Search

Displaying results 1291 - 1300 of 4207 in total
  1. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    Compared to its homolog, [DB09061], CBDV is shortened by two methyl (CH2) groups on its side chain. … In October 2017 CBDV was given orphan designation by the European Medicines Agency for use in Rett Syndrome [L2952] and again in February 2018 for treatment of Fragile X Syndrome [L2951].

  2. Drug

    Atezolizumab

    go.drugbank.com/drugs/DB11595
    ApprovedInvestigational

    Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot ...

  3. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    MBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).

  4. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    The dermatological use of tea tree oil has been investigated by various studies, where several studies have suggested the uses of this oil for the treatment of acne vulgaris, seborrheic dermatitis, and

  5. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. … In vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys.

  6. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803] … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

  7. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64068] NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore this signaling, promoting wakefulness and reducing cataplexy and other

  8. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]

  9. Drug

    Bacampicillin

    go.drugbank.com/drugs/DB01602
    ApprovedWithdrawn

    During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall.

  10. Drug

    Cilgavimab

    go.drugbank.com/drugs/DB16393
    ApprovedInvestigational

    [A243351, A243361, L39411] Cilgavimab is not approved for any indication by the FDA. … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.